Despite the older age and typically more severe disease of DPP4i users, the evidence demonstrates that pre-morbid usage of GLP1-RA is linked with decreased mortality and other deleterious outcomes compared to DPP-4i use in COVID-19 patients (55). The gene discussed is GCG; the disease is COVID-19.